A Phase 2 interventional study of Patiromer in ESRD, Hyperkalemia and End Stage Renal Disease, sponsored by Dominic Raj. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-05-09.
Sponsored by Dominic Raj · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 408th largest by enrollment of the 638 interventional ones that give a count, is one of 37 that started in 2017, is one of 87 in phase 2, and was the 491st registered.
2,114 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:
United Therapeutics · Sites in United States
Ages 40–70
Xeno Holdings (US), LLC dba ChoironeX · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 18+
Basilea Pharmaceutica · Sites in United States
Ages 18–80 · Healthy volunteers
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
765 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 119 · Phase 2 130 · Phase 3 89 · Phase 4 61
First in 1995; this study’s year is marked. 37 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 48 across the 638 interventional studies, 100 across the 121 observational. Of the 611 that completed or were terminated, 267 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 765 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dominic Raj as lead sponsor.
Dominic Raj has 1 study filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
43 of the studies in Kidney Failure, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT05931276Phase 3VA Office of Research and DevelopmentCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes | 2026-12-31 |
| NCT03321656Phase 3Roberto GedalyImpact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile | 2027-03-31 |
| NCT05908084Phase 3Humacyte, Inc.To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | 2027-06 |
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
Add all 43 to your calendar (.ics) → With an account.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia (potassium greater than 5 milliequivalents per liter) is a non-randomized, crossover study. This is an open-label, pilot clinical trial with 3 sequential phases of (a) 2 weeks of no intervention, (b) 12 weeks of Patiromer treatment, and (c) 6 weeks of no intervention. Treatment with Patiromer will be initiated at a dose of 8.4 grams, once daily and observed for a week, then uptitrated to 16.8 grams once daily. Eligible study subjects will collect stool samples and provide blood and urine samples.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm is a 2 week observation period before the start of the Patiromer treatment phase, followed by a 12 week treatment phase, and 6 week no treatment observation phase. Pre-Treatment (Wk 1-2): Observational period. Baseline sample collection of blood and stool. No medication. Treatment (Wk 3-14): Participants will take 8.4 grams of Patiromer once daily for one week, during which serum potassium and gastrointestinal symptoms will be evaluated. If tolerated and in the absence of hypokalemia, the dose will be up-titrated to 16.8 grams once daily for the remaining 11 weeks. Blood and stool will be collected. Post-Treatment (Wk 15-20): Observational period. No medication. Blood and stool will be collected.
Drug: Patiromer
Patiromer will be orally self-administered by participants.
Adverse Events of Participants Taking Patiromer in Lowering Serum Potassium Levels in End Stage Renal Disease (ESRD) Patients With Hyperkalemia Measured by Gastrointestinal Symptom Rating Scale (GSRS)
The Gastrointestinal Symptom Rating Scale was used to measures any potential side effects due to study medication. Survey was administered at Wk 1, Wk 8, Wk 14, and Wk 20. For symptoms (abdomen pain - diarrhea) a score of 0 indicates "no discomfort", 1 = "mild discomfort", 2=moderate, 3=severe; higher score means a worse outcome For stool form, 1=Well formed, 2=Semi formed, 3= Loose, 4= Liquid;higher score means a worse outcome For number of stools per day, 1= \<1, 2=1 or 2, 3=3 or 4, 4=5 or 6,5= 7 or more; higher score means a worse outcome
Time frame: Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)
Serum Potassium Level Through 12 Weeks of Treatment
Blood was collected during Pre-Treatment week 2, Treatment Week 14, and Post-Treatment week 20
Time frame: Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)
Changes in Blood Chemistry During the Study
Time frame: Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)
Stool Electrolytes During the Study Phases
Time frame: Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)
Changes in Plasma Metabolites Using p-Cresol of Hyperkalemic ESRD Patients Treated With Patiromer
Blood and stool samples collected from the ESRD patient will be collected at pre-specified time points and analyzed by untargeted and targeted metabolomics for stool and serum metabolome profiles.
Time frame: Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)
Changes in Gut Microbiome of Hyperkalemic ESRD Patients Treated With Patiromer.
Blood and stool samples collected from the ESRD patient will be collected at pre-specified time points and analyzed by metagenomics for gut microbiome profile.
Time frame: Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-treatment)
| Milestone | Patiromer |
|---|---|
| Started | 27 |
| Completed | 26 |
| Not completed | 1 |
| Milestone | Patiromer |
|---|---|
| Started | 26 |
| Completed | 24 |
| Not completed | 2 |
| Milestone | Patiromer |
|---|---|
| Started | 24 |
| Completed | 24 |
| Not completed | 0 |
The Gastrointestinal Symptom Rating Scale was used to measures any potential side effects due to study medication. Survey was administered at Wk 1, Wk 8, Wk 14, and Wk 20. For symptoms (abdomen pain - diarrhea) a score of 0 indicates "no discomfort", 1 = "mild discomfort", 2=moderate, 3=severe; higher score means a worse outcome For stool form, 1=Well formed, 2=Semi formed, 3= Loose, 4= Liquid;higher score means a worse outcome For number of stools per day, 1= \<1, 2=1 or 2, 3=3 or 4, 4=5 or 6,5= 7 or more; higher score means a worse outcome
| score on a scale | Pre-Treatment | Treatment | Post-Treatment |
|---|---|---|---|
| Abdomen Pain | .24 (.04 to .44) | .23 (0 to .51) | .16 (0 to .32) |
| Heartburn | .08 (0 to .17) | .31 (.02 to .59) | .13 (0 to .32) |
| Acid Reflux | .22 (.03 to .41) | .35 (.06 to .64) | .30 (.04 to .56) |
| Hunger Pains | 0 (0 to 0) | .19 (0 to .38) | .04 (0 to .13) |
| Nausea | .44 (.14 to .75) | .42 (.11 to .74) | .14 (0 to .39) |
| Rumbling Stomach | .34 (.14 to .54) | .23 (0 to .48) | .31 (0 to .62) |
| Bloated | .14 (0 to .28) | .12 (0 to .24) | .14 (0 to .28) |
| Burping | .13 (.02 to .25) | .08 (0 to .18) | .26 (0 to .57) |
| Flatus | .53 (.18 to .88) | .58 (.21 to .94) | .60 (.18 to 1.02) |
| Constipation | .72 (.31 to 1.12) | .65 (.23 to 1.08) | .36 (0 to .72) |
| Diarrhea | .17 (.03 to .32) | .44 (.06 to .82) | .18 (.02 to .34) |
| Stool form | 1.43 (1.20 to 1.66) | 1.62 (1.39 to 1.84) | 1.41 (1.14 to 1.68) |
| Number of stool/days | 1.9 (1.7 to 2.2) | 2.1 (1.8 to 2.4) | 2 (1.8 to 2.2) |
Blood was collected during Pre-Treatment week 2, Treatment Week 14, and Post-Treatment week 20
| mEq/L | Pre-Treatment | Intervention: Treatment | Post-Treatment |
|---|---|---|---|
| Serum Potassium Level Through 12 Weeks of Treatment | 5.7 (5.4 to 5.9) | 5.1 (4.9 to 5.2) | 5.4 (5.2 to 5.6) |
| mg/dl | Pre-Treatment | Treatment | Post-Treatment |
|---|---|---|---|
| Blood Urea Nitrogen | 62.2 (56.9 to 67.5) | 62.6 (57.3 to 67.9) | 59.0 (54.1 to 64.0) |
| Creatinine | 10.4 (9.7 to 11.0) | 10.6 (9.9 to 11.4) | 10.5 (9.9 to 11.1) |
| Sodium | 138.4 (137.3 to 139.5) | 138.5 (137.5 to 139.6) | 139.2 (135.7 to 142.6) |
| Potassium | 5.7 (5.4 to 5.9) | 5.1 (4.9 to 5.2) | 5.4 (5.2 to 5.6) |
| Chloride | 95.2 (94.0 to 96.5) | 95.1 (94.0 to 96.3) | 95.8 (94.6 to 97.0) |
| Carbon Dioxide | 20.3 (19.4 to 21.2) | 20.0 (19.1 to 20.9) | 20.6 (19.5 to 21.7) |
| Calcium | 8.9 (8.7 to 9.1) | 9.1 (8.9 to 9.4) | 8.7 (8.5 to 8.9) |
| Phosphate | 6.0 (5.3 to 6.7) | 6.0 (5.4 to 6.7) | 6.3 (5.7 to 7.0) |
| Magnesium | 2.6 (2.4 to 2.8) | 2.4 (2.3 to 2.6) | 2.5 (2.4 to 2.7) |
| mcg/g | Pre-Treatment | Treatment | Post-Treatment |
|---|---|---|---|
| Sodium | 343 (222 to 464) | 425 (288 to 562) | 360 (241 to 479) |
| Potassium | 4132 (3627 to 4637) | 5923 (4796 to 7050) | 4246 (3858 to 4634) |
| Calcium | 7874 (5799 to 9948) | 13017 (10448 to 15586) | 7635 (5568 to 9703) |
| Phosphate | 7719 (6630 to 8809) | 7067 (5780 to 8354) | 7670 (6341 to 8998) |
| Magnesium | 1923 (1380 to 2466) | 1603 (1347 to 1860) | 1665 (1372 to 1958) |
Blood and stool samples collected from the ESRD patient will be collected at pre-specified time points and analyzed by untargeted and targeted metabolomics for stool and serum metabolome profiles.
No measurements were reported for this outcome.
Blood and stool samples collected from the ESRD patient will be collected at pre-specified time points and analyzed by metagenomics for gut microbiome profile.
No measurements were reported for this outcome.
Collected over The study period during which adverse events must be reported is defined as the period from initiation of the study procedures to the end of the treatment follow-up. In other words, AE documentation should begin when the patient signs the informed consent form. Encourage participants to contact the investigator after the conclusion of the trial if subsequent medical events occur which the participant, or the participant's physician, believes may be related to participation in the research study. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patiromer | 0/27 (0%) | 11/27 (40.7%) | 0/27 (0%) |
| Event | Patiromer |
|---|---|
| HypoglycemiaMetabolism and nutrition disorders | 1/27 |
| HypertensionCardiac disorders | 1/27 |
| Shortness of BreathRespiratory, thoracic and mediastinal disorders | 1/27 |
| FeverInfections and infestations | 1/27 |
| HypoglcymiaMetabolism and nutrition disorders | 1/27 |
| Shortness of BreathRespiratory, thoracic and mediastinal disorders | 1/27 |
| MRSA InfectionInfections and infestations | 1/27 |
| InfectionInfections and infestations | 1/27 |
| Dizzy and DisorientedGeneral disorders | 1/27 |
| NasueaGastrointestinal disorders | 1/27 |
| Event | Patiromer |
|---|---|
| hypomagnesemiaMetabolism and nutrition disorders | 0/27 |
| constipationGastrointestinal disorders | 0/27 |
| diarrheaGastrointestinal disorders | 0/27 |
| Age, Continuous(years) | Patiromer |
|---|---|
| Mean | 56 ± 11 |
| Sex: Female, Male(Participants) | Patiromer |
|---|---|
| Female | 14 |
| Male | 13 |
| Race (NIH/OMB)(Participants) | Patiromer |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 20 |
| White | 7 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Patiromer |
|---|---|
| United States | 27 |
| Body Mass Index (BMI)(kg/m^2) | Patiromer |
|---|---|
| Mean | 33 ± 7 |
| Diabetes(Participants) | Patiromer |
|---|---|
| Count of participants | 11 |
| Coronary Artery Disease(Participants) | Patiromer |
|---|---|
| Count of participants | 3 |
| HIV(Participants) | Patiromer |
|---|---|
| Count of participants | 5 |
23 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Dec 2020, 37 months.
Results were first posted in Mar 2023, 2 years 2 months after primary completion.
Of 41 non-industry phase 2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's 37 months is close to that.
Counting every sponsor, half of 67 studies reached it within 32 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Patiromer